Evidence map›Paper›PMID 41419968›Full record

ArticleBMC chemistry2025

An innovative UV spectrophotometric method for the simultaneous determination of meclizine and pyridoxine in tablets.

Imad Abu Reid, Alkhair Mohamed, Mohamed Hussain

Abstract read
In one paragraph

Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Imad Abu ReidDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, International University of Africa, Khartoum, Sudan. iabureid@hotmail.com.
Alkhair MohamedDepartment of Pharmaceutical Chemistry, College of Pharmacy, Karary University, Omdurman, Sudan.
Mohamed HussainDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum, Sudan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A straightforward, precise, and rapid UV spectrophotometric method has been developed for the simultaneous determination of meclizine (MEC) and pyridoxine (PYR) in binary mixtures. The approach involved two calibration curves: the first was constructed to quantify PYR directly at 290 nm, while the second was used to calculate the concentration ratio (CR) of the mixture at 230 nm. This second curve was generated by plotting the absorbance ratio (AR) against the concentration ratio (CR = [MEC]/[PYR]). Using the experimentally determined concentration ratio (CRₑₓₚ) and the known PYR concentration, the MEC content was calculated as [MEC] = CRₑₓₚ × [PYR]. The method was validated in accordance with ICH Q2 guidelines and demonstrated reliable and consistent performance. When applied to a pharmaceutical formulation, the results expressed as a percentage of the labeled claim were 100.34% ± 0.47 for MEC and 100.04% ± 0.182 for PYR. Furthermore, statistical comparison with a previously published chromatographic method confirmed the equivalence of the two approaches. These results suggest that the developed method is suitable for routine quality control analysis of pharmaceutical preparations containing MEC and PYR. The linearity ranges were 4-20 µg/mL for meclizine and 6-30 µg/mL for pyridoxine and close to 1.00 for both analytes. Excellent precision was demonstrated, with percent Relative Standard Deviations (RSD%) well below 2%. The method also exhibited high accuracy, with analyte recoveries from tablets formulation 99.62 ± 0.34 and 98.92 ± 0.62 for MEC and PYR, respectively.

Indexed as

DeterminationMeclizinePyridoxineTabletsUV spectrophotometry

Identifiers

PMID41419968
PMCPMC12717722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.